Power meets precision: Harnessing piperacillin–tazobactam effectiveness through responsible antimicrobial stewardship

Piperacillin–tazobactam remains an important option for empiric antibiotic therapy in serious infections because of its broad antimicrobial coverage against Gram-negative, Gram-positive, and anaerobic pathogens. Antimicrobial stewardship is a keystone in optimizing piperacillin–tazobactam use, with strategies including early culture collection, reassessment at 48–72 hours, microbiology-guided de-escalation, appropriate treatment duration, and stewardship team review.

Current guideline insights emphasize the continued role of piperacillin–tazobactam in severe infections while limiting its use in extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales infections. The article also highlights optimized dosing strategies, including extended or prolonged infusion, to improve pharmacodynamic target attainment and support responsible antibiotic use.